Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen s Mass Spec Platform Approved as Medical Device By Chinese Health Authorities

NEW YORK, March 4 (GenomeWeb News) - Ciphergen Biosystems' mass spectrometry-based protein analysis platform has been certified as a medical device by China's State Food and Drug Administration, the company's diagnostics division said today.


According to Ciphergen, this is the first time a mass spectrometer has been approved as a medical device in China. The certification opens the door to mass spec-based diagnostic tests, which will have to be approved individually, the company said.


"This represents one more step in preparing the ProteinChip System for diagnostic use on a worldwide basis," said Gail Page, president of Ciphergen's diagnostics division.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.